SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Prestige Consumer Healthcare Inc. (PBH) trades at a trailing P/E of 14.2, forward P/E of 12.5. Trailing earnings yield is 7.02%, forward earnings yield 8.01%. PEG 4.91. Graham Number is $57.87.
Criteria proven by this page:
- VALUE (60/100, Pass) — P/E is below market average (14.2); analyst target implies upside (+16.5%); earnings yield beats bond yields (7.02%).
- Forward P/E 12.5 (down from trailing 14.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 4.91 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 7.02% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 8.01% as earnings recover.
- Analyst consensus target $66.00 (+16.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 73/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PBH
Valuation Multiples
P/E (TTM)14.2
Forward P/E12.5
PEG Ratio4.91
Forward PEG2.15
P/B Ratio1.45
P/S Ratio2.42
EV/EBITDA10.9
Per Share Data
EPS (TTM)$3.90
Forward EPS (Est.)$4.54
Book Value / Share$38.21
Revenue / Share$23.05
FCF / Share$5.58
Yields & Fair Value
Earnings Yield7.02%
Forward Earnings Yield8.01%
Dividend Yield0.00%
Graham Number$57.87
SharesGrow IV$101.45 (+79.1%)
Analyst Target$66.00 (+16.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
28.2 |
1.08 |
3.78 |
3.49 |
- |
| 2017 |
42.4 |
-1.38 |
3.58 |
3.34 |
- |
| 2018 |
5.3 |
0.01 |
1.52 |
1.72 |
- |
| 2019 |
-42.5 |
0.38 |
1.39 |
1.56 |
1.62% |
| 2020 |
13.1 |
-0.03 |
1.59 |
1.93 |
- |
| 2021 |
13.4 |
0.80 |
1.63 |
2.35 |
- |
| 2022 |
13.0 |
0.52 |
1.69 |
2.45 |
- |
| 2023 |
-38.0 |
0.27 |
2.16 |
2.77 |
- |
| 2024 |
17.0 |
-0.05 |
2.15 |
3.17 |
- |
| 2025 |
19.9 |
7.62 |
2.33 |
3.76 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.88 |
$806.25M |
$99.91M |
12.4% |
| 2017 |
$1.30 |
$882.06M |
$69.4M |
7.9% |
| 2018 |
$6.34 |
$1.04B |
$339.57M |
32.6% |
| 2019 |
$-0.69 |
$975.78M |
$-35.8M |
-3.7% |
| 2020 |
$2.78 |
$963.01M |
$142.28M |
14.8% |
| 2021 |
$3.25 |
$943.37M |
$164.68M |
17.5% |
| 2022 |
$4.04 |
$1.09B |
$205.38M |
18.9% |
| 2023 |
$-1.65 |
$1.13B |
$-82.31M |
-7.3% |
| 2024 |
$4.17 |
$1.13B |
$209.34M |
18.6% |
| 2025 |
$4.29 |
$1.14B |
$214.61M |
18.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$4.54 |
$4.46 – $4.55 |
$1.1B |
$1.09B – $1.14B |
4 |
| 2027 |
$4.81 |
$4.79 – $4.83 |
$1.15B |
$1.14B – $1.16B |
5 |
| 2028 |
$5.12 |
$4.95 – $5.29 |
$1.25B |
$1.24B – $1.26B |
2 |
| 2029 |
$5.42 |
$5.32 – $5.68 |
$1.35B |
$1.3B – $1.4B |
1 |
| 2030 |
$5.64 |
$5.54 – $5.91 |
$1.37B |
$1.35B – $1.42B |
1 |
